CIP2A Is Associated with Human Breast Cancer Aggressivity
Open accessPublished version of a preprint
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Purpose: To investigate the clinical relevance of the recently characterized human oncoprotein cancerous inhibitor of protein phosphatase 2A (CIP2A) in human breast cancer. Experimental Design: CIP2A expression (mRNA and protein) was measured in three different sets of human mammary tumors and compared with clinicopathologic variables. The functional role of CIP2A in breast cancer cells was evaluated by small interfering RNA–mediated depletion of the protein followed by an analysis of cell proliferation, migration, anchorage-independent growth, and xenograft growth. Results: CIP2A mRNA is overexpressed (n = 159) and correlates with higher Scarff-Bloom-Richardson grades (n = 251) in samples from two independent human breast cancer patients. CIP2A protein was found to be overexpressed in 39% of 33 human breast cancer samples. Furthermore, CIP2A mRNA expression positively correlated with lymph node positivity of the patients and with the expression of proliferation markers and p53 mutations in the tumor samples. Moreover, CIP2A protein expression was induced in breast cancer mouse models presenting mammary gland–specific depletion of p53 and either BRCA1 or BRCA2. Functionally, CIP2A depletion was shown to inhibit the expression of its target protein c-Myc. Loss of CIP2A also inhibited anchorage-independent growth in breast cancer cells. Finally, CIP2A was shown to support MDA-MB-231 xenograft growth in nude mice. Conclusions: Our data show that CIP2A is associated with clinical aggressivity in human breast cancer and promotes the malignant growth of breast cancer cells. Thus, these results validate the role of CIP2A as a clinically relevant human oncoprotein and warrant further investigation of CIP2A as a therapeutic target in breast cancer treatment. (Clin Cancer Res 2009;15(16):5092–100)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The therapeutic effect of inhibition of CIP2A protein expression in tumor growth has been recently validated by numerous studies [10,14 -18].”
From Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56 (2017) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, CIP2A is required for malignant cellular growth in vitro and for tumor formation in vivo in a number of cancers, and its overexpression broadly promotes cancer cell drug resistance (6)(7)(8)(9)(10)(11).”
From Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias (2021) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“therapeutic impact of inhibition of CIP2A protein expression has been validated by numerous studies across human cancer types18,20,21,23,33,34.”
From Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A (2023) · cites this paper as [34]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As functional consequences of high CIP2A protein expression on tumorigenesis are very well established in numerous recent studies [10,14 -18], it is conceivable that targeting of CIP2A binding to B56 could constitute a first structure-based strategy for therapeutic inhibition of CIP2A protein stability and activity.”
From Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56 (2017) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“CIP2A is a marker of reduced overall survival in certain subgroups of gastric cancer (Khanna et al, 2009), and its expression associates with high grade and lymph node metastasis in breast cancer (Come et al, 2009).”
From Prognostic role of CIP2A expression in serous ovarian cancer (2011) · cites this paper as Come et al, 2009
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, L. D., Smeds, J., George, J., Vega, V. B., Vergara, L., Ploner, A., Pawitan, Y., Hall, P., Klaar, S., Liu, E. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506230102 · Cited by 1,268
Jonkers, J., Meuwissen, R., van der Gulden, H., Peterse, H., van der Valk, M., & Berns, A. (2001) · Nature Genetics · doi:10.1038/ng747 · Cited by 1,053
Self-citationYeh, E., Cunningham, M., Arnold, H., Chasse, D., Monteith, T., Ivaldi, G., Hahn, W. C., Stukenberg, P. T., Shenolikar, S., Uchida, T., et al. (2004) · Nature Cell Biology · doi:10.1038/ncb1110 · Cited by 791
Breast cancer: origins and evolution
Polyak, K. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33295 · Cited by 697
CIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677 · cited 10×
“The specificity of the siRNA used for CIP2A depletion has been reported previously (11).”
BackgroundInfluentialSelf-citationSpecies- and cell type-specific requirements for cellular transformation
Rangarajan, A., Hong, S. J., Gifford, A., & Weinberg, R. A. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.07.009 · Cited by 555
The ubiquitin-specific protease USP28 is required for MYC stability
Popov, N., Wanzel, M., Madiredjo, M., Zhang, D., Beijersbergen, R., Bernards, R., Moll, R., Elledge, S. J., & Eilers, M. (2007) · Nature Cell Biology · doi:10.1038/ncb1601 · Cited by 474
Liu, X., Holstege, H., van der Gulden, H., Treur-Mulder, M., Zevenhoven, J., Velds, A., Kerkhoven, R. M., van Vliet, M. H., Wessels, L. F. A., Peterse, J. L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702969104 · Cited by 474
Self-citationC-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance
Deming, S. L., Nass, S. J., Dickson, R. B., & Trock, B. J. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1522 · Cited by 302
Snail and Slug Play Distinct Roles during Breast Carcinoma Progression
Côme, C., Magnino, F., Bibeau, F., De Santa Barbara, P., Becker, K. F., Theillet, C., & Savagner, P. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0478 · Cited by 259
Self-citation
Cited by
Farrell, A. S., & Sears, R. C. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014365 · Cited by 468
All roads lead to PP 2A: exploiting the therapeutic potential of this phosphatase
Sangodkar, J., Farrington, C. C., McClinch, K., Galsky, M. D., Kastrinsky, D. B., & Narla, G. (2016) · The FEBS Journal · doi:10.1111/febs.13573 · Cited by 312
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth
Sangodkar, J., Perl, A., Tohme, R., Kiselar, J., Kastrinsky, D. B., Zaware, N., Izadmehr, S., Mazhar, S., Wiredja, D. D., O’Connor, C. M., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89548 · Cited by 196
Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer
Janghorban, M., Farrell, A. S., Allen-Petersen, B. L., Pelz, C., Daniel, C. J., Oddo, J., Langer, E. M., Christensen, D. J., & Sears, R. C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317630111 · Cited by 186
“Indeed, endogenous inhibitors of PP2A such as SET and CIP2A have been shown to be up-regulated in a variety of cancers (13, 19).”
BackgroundInfluentialCIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells
Chen, K.-F., Liu, C.-Y., Lin, Y.-C., Yu, H.-C., Liu, T.-H., Hou, D.-R., Chen, P.-J., & Cheng, A.-L. (2010) · Oncogene · doi:10.1038/onc.2010.357 · Cited by 164
Metadata
- Authors
- Côme, C., Laine, A., Chanrion, M., Edgren, H., Mattila, E., Liu, X., Jonkers, J., Ivaska, J., Isola, J., Darbon, J.-M., Kallioniemi, O., Thézenas, S., & Westermarck, J.
- Affiliations
- Authors' Affiliations: 1Centre for Biotechnology, University of Turku and Åbo Akademi University; 2VTT, Technical Research Centre, Turku, Finland; 3Institut de Recherche en Cancérologie de Montpellier, CRLC Val d'Aurelle-Paul Lamarque, Montpellier, France; 4Institute for Molecular Medicine Finland, University of Helsinki, Finland; 5Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; and 6Institute of Medical Technology, University of Tampere, and Tampere University Hospital, Tampere, Finland
- Åbo Akademi University (FI)
- Corresponding author
- Westermarck, Jukka
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2009-08-12
- Volume
- 15
- Issue
- 16
- Pages
- 5092-5100
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2111614147
- Cited by
- 221
- References
- 22
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 1 · 2023: 8 · 2022: 3 · 2021: 8 · 2020: 15 · 2019: 14 · 2018: 13 · 2017: 21 · 2016: 16 · 2015: 23 · 2014: 22 · 2013: 24 · 2012: 19
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Institut Bergonié
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- CIP2A, breast cancer, oncoprotein, tumor aggressiveness, protein phosphatase 2A inhibitor, p53 deficiency, BRCA1, BRCA2, c-Myc, lymph node metastasis, tumor grade, anchorage-independent growth, xenograft tumor growth, therapeutic target
- MeSH terms
- Adult, Aged, Aged, 80 and over, Animals, Autoantigens, Breast Neoplasms, Carcinoma, Female, Humans, Genetic Linkage, Membrane Proteins, Middle Aged, Neoplasm Invasiveness, Neoplasm Metastasis, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic, Xenograft Model Antitumor Assays, RNA, Small Interfering, Intracellular Signaling Peptides and Proteins, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CIP2A Is Associated with Human Breast Cancer Aggressivity. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-08-3283
- The paper
- Côme, C., Laine, A., Chanrion, M., Edgren, H., Mattila, E., Liu, X., Jonkers, J., Ivaska, J., Isola, J., Darbon, J.-M., Kallioniemi, O., Thézenas, S., & Westermarck, J. (2009). CIP2A Is Associated with Human Breast Cancer Aggressivity. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-08-3283
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.